RASTRUM™ Allegro: Advancing 3D Cell Culture with Unmatched Speed and Scalability

The RASTRUM Allegro being used in a lab

Inventia Life Science’s Latest Platform Enhances Drug Discovery and Disease Research

Inventia Life Science has introduced RASTRUM™ Allegro, a cutting-edge 3D cell culture platform that redefines scalability and efficiency in drug discovery and disease research. This next-generation system allows researchers to produce complex, biologically relevant 3D cell models with minimal hands-on time, addressing key challenges in reproducibility and throughput.

Revolutionizing high-throughput 3D cell culture

RASTRUM Allegro delivers precision and scalability, making it easier than ever to generate high-throughput 3D assays. With the ability to print a 96-well plate in just six minutes and support over 35 plates per day, this system ensures researchers can scale experiments without compromising data consistency.

"Scientists know the value of biologically relevant models for advancing their work," said Julio Ribeiro, Founder and CEO of Inventia Life Science. "We developed RASTRUM Allegro to give researchers the ability to generate complex 3D cell models that better represent human biology. The system provides the precision and scalability needed to fuel discovery and reveal deeper biological insights."

Key features of RASTRUM Allegro

  • High-speed bioprinting – Prints a 96-well plate in 6 minutes, a 384-well plate in 9 minutes
  • Enhanced reproducibility – Post-print CVs of <10%, ensuring data consistency
  • Optimized for patient-derived cells – Generates 3.5x more cell models from limited samples
  • Cost-effective – Reduces per-sample costs, increasing research affordability

RASTRUM Allegro is a game-changer for pharmaceutical R&D and translational research, providing a scalable and efficient solution for high-throughput 3D cell culture.

This article has been sourced from a press release and may include content created or refined using AI tools and verified by our editorial team. For the full press release click here.